Wellstar International, Inc./TMI Announces Pending Pressure Ulcer Study on Leg and Foot Ulcers

HOLLAND, OH--(Marketwire - January 14, 2009) - Wellstar International, Inc. (OTCBB: WLSI), a provider of specialized diagnostic software and equipment, announced today that its wholly owned subsidiary, Trillennium Medical Imaging (“TMI”), has begun negotiations for a pressure ulcer study focused on ulcers caused by diabetic foot and venous legs. The Company is currently in talks with several major teaching and research universities, the goal of which is to secure a clinical partner for this study. Wellstar anticipates that the study could start as early as March 2009.

In the U.S. alone, approximately 1.5 million adults are treated each year for pressure ulcers (bedsores) with associated health care costs of over $5 billion. Regrettably, more than 65,000 patients die each year from complications related to these ulcers. Pressure ulcers represent one of four of the most common and costly deficiencies found in long-term care facilities.

A diabetic foot ulcer is a sore or wound that often occurs in people with diabetes; these ulcers may be difficult to heal, susceptible to infection and may lead to amputation of the affected toe, foot or leg if not treated. Over 850,000 chronic diabetic ulcers are diagnosed in the U.S. each year. Approximately 3 million diabetic patients will develop an ulcer and 25% of these patients will have a foot amputated.

Venous leg ulcer is a sore or wound that is caused by poor circulation of blood in the veins of the legs usually caused by faulty valves allowing pressure to build up in the veins. This pressure causes damage to the tiny blood vessels in the skin, making the skin become thin and inflamed, and causing the death of tissue cells leading to the ulcer.

The Company’s infrared imaging system involves the detection and recording of skin temperature and injury patterns, providing visual and quantitative documentation to accurately capture body temperature data. The Company’s system map changes in skin blood flow by translating temperature data into pictures. The interpretation of these temperatures and thermal patterns can play an important role in detecting these sores at an early stage.

Wellstar/TMI CEO John Antonio stated, “We are looking forward to working with one of the clinical partners that we are currently communicating with about this planned study. Early detection of pressure ulcers is critical and can actually help prevent ulcer outbreaks among patients. The TMI infrared imaging system is a viable tool, and should soon prove to be the medical standard for predicting and preventing pressure ulcers in the medical community. "

ABOUT WELLSTAR INTERNATIONAL, INC.

Wellstar International, Inc., through its wholly owned operating subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to become a leading diagnostic company in the health care industry. TMI has developed and is marketing fully calibrated and functional, thermal imaging systems that utilize state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. More information on the Company and its unique diagnostic software and product line is available on Wellstar’s corporate Website by visiting: www.wellstar.us

FORWARD-LOOKING STATEMENTS

This press release contains statements, which may constitute ‘forward-looking statements’ within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.